Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > News

<< Previous

Bullboard Posts

Next >>

Comment by BioTeckon Nov 11, 2022 3:05pm

270 Views

Post# 35092274

RE:RE:News

Good post quest. One of the big concerns I have is that this stock is mostly held by retailers and no institutions. The wild swings on extremely low volume are likely do to this fact. We pay over a million dollars to multiple pr entities which are literally doing nothing. This all goes back to management being incompetent

quest13 wrote: To answer the recent question of BioTeck and view of Metalsguy1; I believe it was worth the wait to see that things are going well; although I wish that these things could go faster. I also have no intention to sell any of my holdings at today’s prices.

Well! we now see what Dr. Toleikis was referring to in his fireside chat and it was not our fabled “007” being processed; but as I understand it; it was the starting of a new cohort which has turned out to be “up to” 7 persons. I have gone back and relistened and believe my understanding is correct.

My belief from reading the tea leaves and putting it into my own common understanding language, is that the fabled “007” may or may not be in the new cohort for “up to” 7 people who have been approved by all who must approve such things.

In the group who must agree is the approval of a protocol amendment by the University of Chicago Institutional Review Board (IRB) and no objections from FDA, which has now been confirmed.

I also see that the first cohort has been capped at 6 persons so either “007” is part of the new group, or he had immune issues. In any case we shall probably hear no more of him or her as a separate individual.

In any case we now know that of the first 6 people Implanted 3 are insulin free and the next 3 are “proceeding normally through the trial”. I expect that we will hear of the second set of three being insulin free in due course although I do not believe we will hear as soon as I would like.

I find it very good for us as shareholders that “approval of a protocol amendment by the University of Chicago Institutional Review Board (IRB) and no objections from FDA” is now part of accepted fact.

I regard this as great news; although I am still horrified that enough of those who got involved in the early stages are sufficiently satisfied with their profits when they sell in the sub $1.00 range and simply take the money and run.